HAEMATO AG: Capital increase from authorized capital

Schönefeld (pta039/05.05.2017/17:45 UTC+2) Publication of inside information in accordance with Article 17 MAR

HAEMATO AG: Capital increase from authorized capital with the exclusion of the subscription rights of the existing shareholders decided and successfully implemented.

The Management Board of HAEMATO AG, Schönefeld, (ISIN: DE0006190705) decided today, with the approval of the Supervisory Board, on the basis of the authorized capital of the company to increase the share capital by EUR 1,202,102.00 excluding shareholders' subscription rights. The capital increase has been successfully implemented.

The share capital of the company will increase by EUR 1,201,102.00 from EUR 20,778,898.00 to EUR 21,980,000.00 with the short-term expected entry of the capital increase in the commercial register.

The new shares were placed at a price of EUR 6.20 per share. The shares were subscribed by MPH Mittelstandische Pharma Holding AG.

The company generated gross issue proceeds of around EUR 7.4 million from the capital increase. The proceeds from the capital increase are intended to further strengthen the equity of HAEMATO AG and create the prerequisites for the consistent implementation of the growth strategy of the HAEMATO Group. In particular, the development of products with attractive margins is to be further expanded.

First Berlin acted as advisor to HAEMATO AG.

Communicating person and contact:
Dr. Christian Pahl
CEO

(end)

Emitter:	HAEMATO AG Lilienthalstraße 5c 12529 Schönefeld Germany
Contact Person:	Dr. Christian Pahl
Phone:	+49 30 8973086-70
E-Mail:	ir@haemato.de
Website:	www.haemato-ag.de
ISIN(s):	DE0006190705 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate